Recombinant Monoclonal Antibodies, from Tumor Targeting to Cancer Immunotherapy: A Critical Overview

In view of the explosion of the present clinical use of monoclonal antibodies (mAbs), not only in the treatment of cancer, but also of autoimmune diseases, I was asked to review the development of mAbs in tumor diagnosis and therapy, with some illustrations of our own contribution in the field. The...

Full description

Saved in:
Bibliographic Details
Published in:Molecular biology (New York) 2017-11, Vol.51 (6), p.887-899
Main Author: Mach, J.-P.
Format: Article
Language:English
Subjects:
Autoimmune diseases
Biochemistry
Biomedical and Life Sciences
Bispecific antibodies
Cancer
Cancer immunotherapy
Current Trends in the Application of Monoclonal Antibodies Special Issue
Cytotoxicity
Hematology
Human Genetics
Immunoglobulins
Immunotherapy
Life Sciences
Lymphocytes
Lymphocytes T
Medical treatment
Monoclonal antibodies
Motivation
Targeted cancer therapy
Tumor cells
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In view of the explosion of the present clinical use of monoclonal antibodies (mAbs), not only in the treatment of cancer, but also of autoimmune diseases, I was asked to review the development of mAbs in tumor diagnosis and therapy, with some illustrations of our own contribution in the field. The initial use of radiolabeled mAbs for tumor targeting and radioimmunotherapy led to the extensive clinical application of unlabeled, “humanized” mAbs for cancer therapy, which I describe with a critical perspective. The introduction of recombinant bispecific antibodies, capable of bridging T lymphocytes with tumor cells and inducing killing of the cancer cells, was found to be mostly active in the treatment of hematological malignancies. Most interestingly, the use of mAbs not directed to the tumor cells, but to inhibitory receptors expressed by cytotoxic T lymphocytes, which trigger them to kill the cancer cells, represents a new form of active cancer immunotherapy. My motivation in writing this review was related to my long-term interactions with several Russian scientists, mentioned at the end of this article.
ISSN:0026-8933
1608-3245
DOI:10.1134/S0026893317060115